A share price of SOPHiA Genetics SA [SOPH] is currently trading at $72990.0, up 1908935%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SOPH shares have gain 4.83% over the last week, with a monthly amount glided 5.56%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
SOPHiA Genetics SA [NASDAQ: SOPH] stock has seen the most recent analyst activity on December 18, 2024, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $11. Previously, Morgan Stanley downgraded its rating to Equal-Weight on August 07, 2024, and dropped its price target to $5. On June 27, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $6 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $8 on November 29, 2023. BTIG Research started tracking with a Buy rating for this stock on January 03, 2023, and assigned it a price target of $6. In a note dated November 23, 2022, Credit Suisse initiated an Neutral rating and provided a target price of $2 on this stock.
SOPHiA Genetics SA experienced fluctuations in its stock price throughout the past year between $2.58 and $5.00. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. SOPHiA Genetics SA [NASDAQ: SOPH] shares were valued at $72990.0 at the most recent close of the market. An investor can expect a potential drop of -99.99% based on the average SOPH price forecast.
Analyzing the SOPH fundamentals
Trailing Twelve Months sales for SOPHiA Genetics SA [NASDAQ:SOPH] were 67.17M which represents 12.68% growth. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.95%, Pretax Profit Margin comes in at -0.96%, and Net Profit Margin reading is -0.99%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.63 and Total Capital is -0.54. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.35.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for SOPHiA Genetics SA [NASDAQ:SOPH] is 3.11. Also, the Quick Ratio is 2.94, while the Cash Ratio stands at 2.37. Considering the valuation of this stock, the price to sales ratio is 3.02, the price to book ratio is 2.37.
Transactions by insiders
Recent insider trading involved VINCENT OSSIPOW, Director, that happened on Jun 20 ’25 when 18443.0 shares were purchased. Officer, ROSS J MUKEN completed a deal on Jun 20 ’25 to buy 14509.0 shares. Meanwhile, Director JURGI CAMBLONG bought 43135.0 shares on May 19 ’25.
